MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Arcus Biosciences Inc

Geschlossen

BrancheGesundheitswesen

8.25 -1.9

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.16

Max

8.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2M

-94M

Verkäufe

-22M

26M

EPS

-1.03

Gewinnspanne

-361.538

Angestellte

627

EBITDA

-89M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+250.96% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-234M

834M

Vorheriger Eröffnungskurs

10.15

Vorheriger Schlusskurs

8.25

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Arcus Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Apr. 2025, 17:01 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25. Apr. 2025, 16:10 UTC

Ergebnisse
Wichtige Markttreiber

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26. Apr. 2025, 18:14 UTC

Ergebnisse

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26. Apr. 2025, 15:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26. Apr. 2025, 08:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

25. Apr. 2025, 21:24 UTC

Top News

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25. Apr. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

25. Apr. 2025, 20:45 UTC

Top News

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25. Apr. 2025, 20:39 UTC

Ergebnisse

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25. Apr. 2025, 20:37 UTC

Top News

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25. Apr. 2025, 20:19 UTC

Top News

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25. Apr. 2025, 20:15 UTC

Ergebnisse

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25. Apr. 2025, 19:23 UTC

Market Talk

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25. Apr. 2025, 19:18 UTC

Market Talk

Oil Futures End Choppy Week With Losses -- Market Talk

25. Apr. 2025, 18:47 UTC

Market Talk

Gold Extends Pullback to Close Week -- Market Talk

25. Apr. 2025, 18:39 UTC

Top News

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25. Apr. 2025, 18:34 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25. Apr. 2025, 18:32 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

25. Apr. 2025, 18:32 UTC

Market Talk
Ergebnisse

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25. Apr. 2025, 18:08 UTC

Ergebnisse

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25. Apr. 2025, 17:55 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25. Apr. 2025, 17:40 UTC

Top News

Consumers Continue to Sour on the Economy -- 4th Update

25. Apr. 2025, 17:38 UTC

Ergebnisse

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25. Apr. 2025, 17:07 UTC

Market Talk

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25. Apr. 2025, 16:54 UTC

Market Talk
Ergebnisse

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25. Apr. 2025, 16:46 UTC

Ergebnisse

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25. Apr. 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

25. Apr. 2025, 16:12 UTC

Top News

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25. Apr. 2025, 16:03 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. Apr. 2025, 15:52 UTC

Market Talk

Grains Mixed on Low Volume Trade -- Market Talk

Peer-Vergleich

Kursveränderung

Arcus Biosciences Inc Prognose

Kursziel

By TipRanks

250.96% Vorteil

12-Monats-Prognose

Durchschnitt 29.13 USD  250.96%

Hoch 46 USD

Tief 14 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcus Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.01 / 8.41Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.